GSE99756 Transcriptome profiling of HepG2 cells in Cdc20 overexpressed and downregulated condition
Contributor : Susanta RoychoudhurySeries Type : Expression profiling by arrayOrganism : Homo sapiensCdc20 acts as a regulatory protein interacting with many other proteins at multiple points in the cell cycle. Here we tried to explore the novel transcription regulatory function of Cdc20 by means of altering Cdc20 level in HepG2 cells. We transiently over expressed Flag tagged Cdc20 (F) and siRNA mediated knocked down Cdc20(S) in HepG2 cell line and performed whole genome microarray analysis using illumina BeadChip Array. Significantly altered genes were subjected to the analysed by Ingenuity pathway analysis software (Build version: 302937) and crucial cellcycle and apoptotic pathways were found to be altered. These pathways could further be explored as anticancer therapy in liver carcinoma.
Asian J Surg. 2022 Jan 12:S1015-9584(21)00850-2. doi: 10.1016/j.asjsur.2021.12.068. Online ahead of print.NO ABSTRACTPMID:35031179 | DOI:10.1016/j.asjsur.2021.12.068
Abstract ObjectivesTo determine the realized tumor to normal ratios (TNRs) in patients undergoing radiation segmentectomies (RS); determine the relationship between TNRs and particle load in transarterial radioembolization (TARE).MethodsIn total, 148 patients who underwent 184 TARE procedures for hepatocellular carcinoma were evaluated. Post treatment SPECT CT bremsstrahlung imaging was analyzed utilizing Simplicit90y ™ to determine realized TNR. A model which normalized activity across all RS treatments to a level that would achieve 400 Gy by unicompartmental dosing was created to determine the affect rea...
ConclusionsThe LR-M category was commonly used to characterize non-HCC malignancies, but also included 29% of HCC. The frequencies of the different LR-M imaging features were variable, with rim APHE showing the highest frequency in non-HCC malignancies.Key Points• In the LR-M category using LI-RADS v2018 for MRI,the pooled percentage of malignancies in general was 96%, with 29% HCC and 67% non-HCC malignancies, while the remaining 4% was benign entity.• The study type and inclusion of benign lesions were significant factors contributing to substantial heterogeneity among included studies.• The frequencies of...
Cell Death &Differentiation, Published online: 15 January 2022; doi:10.1038/s41418-022-00929-wNon-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation
ConclusionThis review provides a platform for HCC and liver xenografts and highlights studies performed to understand gene functionality and drug efficacy in vivo in zebrafish.
ConclusionsThe eradication of HCV before MTA therapy maintained liver function and led to a prolonged treatment period and improved overall survival of HCV-related HCC patients. We should not overlook the benefits of HCV eradication in HCC patients.
Various risk scores have been developed to predict hepatocellular carcinoma (HCC) occurrence in patients with chronic hepatitis B (CHB) treated with or without nucleos(t)ide analogues. However, the methodologies adopted in previous studies were confined to conventional statistical methods, such as logistic regression analyses. Kim and coworkers aimed to develop and validate an artificial intelligence-assisted prediction model of HCC risk. A model was developed using 6,051 patients with CHB who received entecavir or tenofovir from 4 hospitals in Korea.
Condition: Hepatocellular Carcinoma Interventions: Procedure: Radiofrequency ablation; Procedure: Liver resection; Procedure: Liver transplantation Sponsor: University Health Network, Toronto Completed
CONCLUSION: The expression of ARID1A could be used to predict the outcome of HCC. It is closely related to tumor immune cell infiltration.PMID:35028302 | PMC:PMC8752298 | DOI:10.1155/2022/3163955
Br J Clin Pharmacol. 2022 Jan 13. doi: 10.1111/bcp.15233. Online ahead of print.ABSTRACTAIMS: Patients with advanced urothelial carcinoma (UC) who progress after platinum-based chemotherapy have a poor prognosis, and there is a medical need to improve current treatment options. Ramucirumab plus docetaxel significantly improved progression-free survival but not overall survival (OS) in platinum-refractory advanced UC (RANGE trial; NCT02426125). Here, we report the exposure-response (ER) of ramucirumab plus docetaxel using data from the RANGE trial.METHODS: Pharmacokinetic (PK) samples were collected (cycle 1-3, 5 ,9 [day 1]...